CAMBRIA-1 Study: Extended Adjuvant Therapy With Camizestrant vs. Standard ET in Patients With ER+/HER2- Early BC and an Intermediate or High Risk of Recurrence

31 views
November 3, 2023
0 Comments
Login to view comments. Click here to Login